Impact of Ebola epidemics on the daily operation of existing systems in Eastern Democratic Republic of the Congo: a brief review
CONCLUSION: National leadership has not yet taken the lead in strategic, operational, or financial aspects. Therefore, national leaders should double their efforts and awareness to encourage local fundraising, sufficient budget al.location, infrastructure construction, equipment provision, and staff training, to effectively support a holistic approach in response to outbreaks, providing effective results, and all types of research activities.PMID:38240249 | DOI:10.1080/13696998.2024.2305009 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 19, 2024 Category: Health Management Authors: Daniel Mukadi-Bamuleka Antoine Nkuba-Ndaye Placide Mbala-Kingebeni Steve Ahuka-Mundeke Jean-Jacques Muyembe-Tamfum Source Type: research
Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results
CONCLUSIONS: With longer-term survival data, axi-cel continues to represent a cost-effective option versus tisa-cel for treatment of r/r LBCL among patients who have previously received ≥2 lines of systemic therapy, from a US payer perspective.PMID:38240256 | DOI:10.1080/13696998.2024.2305558 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 19, 2024 Category: Health Management Authors: Olalekan O Oluwole Markqayne D Ray Neil Davies Rory Bradford Calum Jones Anik R Patel Frederick L Locke Source Type: research
Validation of overall survival extrapolations made by TLV in the assessment of cost-effectiveness of oncology drugs in Sweden - A pilot study comparing extrapolated and observed life-years gained
CONCLUSIONS: We conclude that it is feasible to validate OS extrapolations by comparing extrapolated and observed life-years. Even if survival extrapolations are reasonably accurate for the treatment group, this may still imply that extrapolations of LYs gained deviates to a larger extent. Follow-up studies on OS should be carried out to an increased extent to be able to validate, update and improve OS extrapolations in cost-effectiveness analysis of oncology drugs.PMID:38225911 | DOI:10.1080/13696998.2024.2304459 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 16, 2024 Category: Health Management Authors: Jonas Bj örnerstedt Hannah Almqvist Douglas Lundin Niklas Zethraeus Source Type: research
Correction
J Med Econ. 2024 Jan-Dec;27(1):165-166. doi: 10.1080/13696998.2024.2305006. Epub 2024 Jan 13.NO ABSTRACTPMID:38217430 | DOI:10.1080/13696998.2024.2305006 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 13, 2024 Category: Health Management Source Type: research
Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation
CONCLUSION: Incremental costs of progression to mCRPC are significant, with the majority of costs driven by higher PC-related costs. Using contemporary data, this study highlights the importance of utilizing effective therapies that slow progression and reduce healthcare resource demands despite the initial investment in treatment costs.PMID:38204397 | DOI:10.1080/13696998.2024.2303890 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 11, 2024 Category: Health Management Authors: Deborah R Kaye Ibrahim Khilfeh Erik Muser Laura Morrison Frederic Kinkead Ana Urosevic Patrick Lefebvre Dominic Pilon Daniel J George Source Type: research
Correction
J Med Econ. 2024 Jan-Dec;27(1):153. doi: 10.1080/13696998.2024.2304418. Epub 2024 Jan 10.NO ABSTRACTPMID:38197782 | DOI:10.1080/13696998.2024.2304418 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 10, 2024 Category: Health Management Source Type: research
Adverse events and costs among non-metastatic castration-resistant prostate cancer patients
CONCLUSION: There is significant HCRU and cost burden among nmCRPC patients treated with ARAs developing AEs, highlighting the need for treatments with improved tolerability. Additional studies are warranted to include recently approved agents.PMID:38174553 | DOI:10.1080/13696998.2023.2299179 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 4, 2024 Category: Health Management Authors: Sreevalsa Appukkuttan Jianying Yao Jamie Partridge Sheldon X Kong Jacqueline Parkin Stephen J Freedland Source Type: research
Why Are Digital Health Policies Crucial?
J Med Econ. 2024 Jan 4:1-6. doi: 10.1080/13696998.2024.2302254. Online ahead of print.NO ABSTRACTPMID:38174851 | DOI:10.1080/13696998.2024.2302254 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 4, 2024 Category: Health Management Authors: Ahmad Z Al Meslamani Source Type: research
Adverse events and costs among non-metastatic castration-resistant prostate cancer patients
CONCLUSION: There is significant HCRU and cost burden among nmCRPC patients treated with ARAs developing AEs, highlighting the need for treatments with improved tolerability. Additional studies are warranted to include recently approved agents.PMID:38174553 | DOI:10.1080/13696998.2023.2299179 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 4, 2024 Category: Health Management Authors: Sreevalsa Appukkuttan Jianying Yao Jamie Partridge Sheldon X Kong Jacqueline Parkin Stephen J Freedland Source Type: research
Why Are Digital Health Policies Crucial?
J Med Econ. 2024 Jan 4:1-6. doi: 10.1080/13696998.2024.2302254. Online ahead of print.NO ABSTRACTPMID:38174851 | DOI:10.1080/13696998.2024.2302254 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 4, 2024 Category: Health Management Authors: Ahmad Z Al Meslamani Source Type: research
Adverse events and costs among non-metastatic castration-resistant prostate cancer patients
CONCLUSION: There is significant HCRU and cost burden among nmCRPC patients treated with ARAs developing AEs, highlighting the need for treatments with improved tolerability. Additional studies are warranted to include recently approved agents.PMID:38174553 | DOI:10.1080/13696998.2023.2299179 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 4, 2024 Category: Health Management Authors: Sreevalsa Appukkuttan Jianying Yao Jamie Partridge Sheldon X Kong Jacqueline Parkin Stephen J Freedland Source Type: research
Why Are Digital Health Policies Crucial?
J Med Econ. 2024 Jan 4:1-6. doi: 10.1080/13696998.2024.2302254. Online ahead of print.NO ABSTRACTPMID:38174851 | DOI:10.1080/13696998.2024.2302254 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 4, 2024 Category: Health Management Authors: Ahmad Z Al Meslamani Source Type: research
Adverse events and costs among non-metastatic castration-resistant prostate cancer patients
CONCLUSION: There is significant HCRU and cost burden among nmCRPC patients treated with ARAs developing AEs, highlighting the need for treatments with improved tolerability. Additional studies are warranted to include recently approved agents.PMID:38174553 | DOI:10.1080/13696998.2023.2299179 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 4, 2024 Category: Health Management Authors: Sreevalsa Appukkuttan Jianying Yao Jamie Partridge Sheldon X Kong Jacqueline Parkin Stephen J Freedland Source Type: research
Why Are Digital Health Policies Crucial?
J Med Econ. 2024 Jan 4:1-6. doi: 10.1080/13696998.2024.2302254. Online ahead of print.NO ABSTRACTPMID:38174851 | DOI:10.1080/13696998.2024.2302254 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 4, 2024 Category: Health Management Authors: Ahmad Z Al Meslamani Source Type: research
